Efficacy of Terlipressin and Albumin for treatment of Hepatorenal Syndrome of a tertiary care hospitals
Bilal Rafique Malik, Hamid Khalil, Mehwish Ejaz
747
ABSTRACT
Background: Hepatorenal
syndrome (HRS) is a fatal complication of advanced cirrhosis with ascites and
liver failure, with nearly 50% of patients dying within 2 weeks after the onset.
HRS reportedly occurs in 7%–15% of patients with advanced cirrhosis and
ascites; the estimated annual incidence of HRS in the United States is
approximately 9,000–14,000 patients
Aim: To compare the efficacy of
Terlipression and albumin for treatment of hepatorenal syndrome
Setting: Department of Medicine, East Medical Ward , Mayo Hospital, Lahore.
Duration: .From January to December 2019.
Methods:: Randomized control trial. Patients
were randomly allocated in 2 groups by using computer generated random numbers
table,30, 30 patients included in Group A and
Group B. Terlipression plus Albumin was given in group A and dopamine
was given in group B. Independent sample t test was
applied for continuous variables and chi square test was used for categorical parameters.
P value < 0.05 was considered as statistically significant
Results: The mean age of Group A was 38.43±10.94years and the mean
age of Group B was 40.56±12.44years. There were 13(43.3%) and 12(40%) females
in group A while there were 17(56.7%) females and 18(60%) females in group B. Among groups, Efficacy was present
in 21(70%) in group A patients out of which 30 cases. But among controls, Efficacy
was present in 12(40%) in
group B patients out of which 30 cases. There was statistically significant difference was observed between both groups
(p<0.001)
Conclusions: Terlipressin with albumin an effective therapeutic intervention
for hepatorenal syndrome as compare to dopamine
Key words: Terlipressin, Albumin, Hepatorenal syndrome,,
ABSTRACT
Background: Hepatorenal
syndrome (HRS) is a fatal complication of advanced cirrhosis with ascites and
liver failure, with nearly 50% of patients dying within 2 weeks after the onset.
HRS reportedly occurs in 7%–15% of patients with advanced cirrhosis and
ascites; the estimated annual incidence of HRS in the United States is
approximately 9,000–14,000 patients
Aim: To compare the efficacy of
Terlipression and albumin for treatment of hepatorenal syndrome
Setting: Department of Medicine, East Medical Ward , Mayo Hospital, Lahore.
Duration: .From January to December 2019.
Methods:: Randomized control trial. Patients
were randomly allocated in 2 groups by using computer generated random numbers
table,30, 30 patients included in Group A and
Group B. Terlipression plus Albumin was given in group A and dopamine
was given in group B. Independent sample t test was
applied for continuous variables and chi square test was used for categorical parameters.
P value < 0.05 was considered as statistically significant
Results: The mean age of Group A was 38.43±10.94years and the mean
age of Group B was 40.56±12.44years. There were 13(43.3%) and 12(40%) females
in group A while there were 17(56.7%) females and 18(60%) females in group B. Among groups, Efficacy was present
in 21(70%) in group A patients out of which 30 cases. But among controls, Efficacy
was present in 12(40%) in
group B patients out of which 30 cases. There was statistically significant difference was observed between both groups
(p<0.001)
Conclusions: Terlipressin with albumin an effective therapeutic intervention
for hepatorenal syndrome as compare to dopamine
Key words: Terlipressin, Albumin, Hepatorenal syndrome,,